公开(公告)号：EP3408673A1

公开(公告)日：2018-12-05

申请号：EP17701686.2

申请日：2017-01-24

申请人： Sanofi

发明人： CHIRON-BLONDEL, Marielle ,  DREYMANN, Jennifer ,  PACCARD, Caroline

IPC分类号： G01N33/574

摘要： The present invention concerns the use of VCAM-1, ICAM-1 and/or PIGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.

公开(公告)号：EP3256160A1

公开(公告)日：2017-12-20

申请号：EP16704440.3

申请日：2016-02-12

申请人： SANOFI

发明人： BUSSEMER, Till ,  PIEPER, Annette ,  SAGI, Dijana ,  STREBE, Nina ,  YOUSSEFF, Ahmed

IPC分类号： A61K39/395 ,  C07K16/24

CPC分类号： A61K39/39591 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  C07K16/241 ,  C07K16/2866 ,  C07K2317/94

摘要： The present invention concerns stable pharmaceutical compositions for monoclonal antibodies, for example IgG antibodies. The invention further relates to medicaments and treatments using the pharmaceutical compositions of the invention. Additionally, the invention relates to a kit comprising at least one of the pharmaceutical compositions of the invention and a method for reducing aggregation of antibodies.

公开(公告)号：EP2879694A1

公开(公告)日：2015-06-10

申请号：EP13745404.7

申请日：2013-08-02

申请人： SANOFI

发明人： ASSADOURIAN, Sylvie ,  CASTAN, Rémi ,  MAGHERINI, Emmanuelle

IPC分类号： A61K38/18 ,  A61K9/00 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00

CPC分类号： A61K9/0019 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K38/179 ,  A61K38/1866 ,  B65D85/70 ,  A61K2300/00

摘要： Article of manufacture comprising a packaging material, a polypeptide of SEQ ID NO:1, aflibercept or ziv-aflibercept or a biosimilar thereof, and a label comprising a printed statement which informs a prospective user of adverse events or adverse reactions.

公开(公告)号：EP2315781B1

公开(公告)日：2015-05-06

申请号：EP09784478.1

申请日：2009-07-07

申请人： SANOFI

发明人： BAURIN, Nicolas ,  BERNE, Pierre-François ,  BLANCHE, Francis ,  BONO, Françoise ,  CAMERON, Béatrice ,  DABDOUBI, Tarik ,  HERBERT, Corentin ,  MIKOL, Vincent ,  REMY, Elisabeth

IPC分类号： C07K16/28 ,  C12N15/13 ,  C12N5/18 ,  A61K39/395 ,  A61P35/00 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

公开(公告)号：EP2067863A3

公开(公告)日：2013-11-06

申请号：EP08014103.9

申请日：2001-09-06

申请人： Aventis Pharma S.A. ,  Université Louis Pasteur, U.L.P.

发明人： Nicolau, Yves

IPC分类号： C07K14/00 ,  C07K16/00 ,  A61P25/28 ,  C07K16/18 ,  C07K14/79 ,  C07K14/47 ,  A61K38/00

CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55555 ,  C07K14/4711 ,  C07K14/4713 ,  C07K14/79 ,  C07K2319/00 ,  C12N2799/026

摘要： The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion proteins encoded therein.

摘要翻译： 本发明一般涉及疾病状态的检测，治疗或预防。 具体地，本发明涉及淀粉样变性或淀粉样蛋白相关疾病的检测，治疗或预防。 本发明还包括包含治疗性疫苗，抗血清和分子构建体的方法和组合物，其包含其中编码的表达载体和融合蛋白。

公开(公告)号：EP2550975A1

公开(公告)日：2013-01-30

申请号：EP11305999.2

申请日：2011-07-29

申请人： SANOFI

发明人： Besret, Laurent ,  Carrez, Chantal ,  Payrard, Sandrine

IPC分类号： A61K47/48 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00

CPC分类号： A61K39/3955 ,  A61K31/537 ,  A61K39/39558 ,  A61K47/48561 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2887 ,  A61K2300/00

摘要： A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+ CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.

摘要翻译： 抗CD19类美登素的免疫缀合物和利妥昔单抗的组合物用于治疗CD19 + CD20 + B细胞恶性肿瘤中的具体的非何杰金氏淋巴瘤的症状。

公开(公告)号：EP2397495A1

公开(公告)日：2011-12-21

申请号：EP10305660.2

申请日：2010-06-21

申请人： SANOFI

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07K16/28

CPC分类号： C07K16/2803 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and antibodies that bind to an epitope which is similar to the conformational epitope recognized by antibody from hybridoma clone 390. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases.

摘要翻译： 本发明公开了特异性结合人血小板膜蛋白糖蛋白VI（GPVI）及其单价片段或衍生物的新型抗体。 本发明的抗体是来自杂交瘤克隆390的抗体和结合与来自杂交瘤克隆390的抗体识别的构象表位相似的表位的抗体。这些抗体和Fab片段能够阻断胶原蛋白结合并因此阻止血小板活化， 胶原。 本发明还涉及用于生产所公开的抗体和Fab片段的杂交瘤克隆和表达质粒。 本发明进一步涉及单价抗体片段用于制造用于治疗血栓形成和其他血管疾病的研究，诊断和免疫治疗剂的用途。

公开(公告)号：EP2364324A1

公开(公告)日：2011-09-14

申请号：EP09774724.0

申请日：2009-11-05

申请人： SANOFI

发明人： HALL, Diana ,  JIMENEZ, Maria ,  POUSSIN, Carine ,  THORENS, Bernard

IPC分类号： C07K14/47 ,  A61K38/57

CPC分类号： C12N15/113 ,  C07K14/4715 ,  C12N2310/14

摘要： The present invention concerns Plac8, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Plac8 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Plac8 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

公开(公告)号：EP1639139B1

公开(公告)日：2011-07-27

申请号：EP04767370.2

申请日：2004-06-17

申请人： Aventis Pharma S.A.

发明人： MACE, Sandrine ,  RICARD, Sylvain ,  COUSIN, Emmanuelle ,  PRADIER, Laurent ,  BENAVIDES, Jesus ,  DELEUZE, Jean-François

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6881 ,  C12Q2600/156

摘要： The invention relates to methods for the diagnosis or prognosis of Alzheimer's disease in an individual. An inventive method has at least one step for detecting the presence or the absence of the minority allele of polymorphism rs908832 of gene ABCA2. The presence of the minority allele of polymorphism rs908832 of gene ABCA2 indicates that the individual can be afflicted with Alzheimer's disease or is presently at increased risk of developing Alzheimer's disease.

公开(公告)号：EP2336188A1

公开(公告)日：2011-06-22

申请号：EP09306283.4

申请日：2009-12-18

申请人： Sanofi-Aventis

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07K16/28

CPC分类号： C07K16/2803 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and antibodies that bind to an epitope which is similar to the conformational epitope recognized by antibody from hybridoma clone 390. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases.

摘要翻译： 本发明公开了特异性结合人血小板膜蛋白Glycoprotein VI（GPVI）及其一价片段或衍生物的新型抗体。 本发明的抗体是来自杂交瘤克隆390的抗体和结合表位的抗体，所述表位类似于来自杂交瘤克隆390的抗体识别的构象表位。这些抗体和Fab片段能够阻断胶原结合并因此阻止血小板活化 胶原。 本发明还涉及用于产生所公开的抗体和Fab片段的杂交瘤克隆和表达质粒。 本发明还涉及一价抗体片段用于制备用于治疗血栓形成和其它血管疾病的研究，诊断和免疫治疗剂的用途。